Showing results (41-50 of 259) with videos related to
Sort By:
Pageof 26
Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 1, 2018
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese studyTing-Hui Wu, Lukas Jyuhn-Hsiarn Lee, Chang-Tsu Yuan, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2019
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung CancerChia-Chi Hsu, Bin-Chi Liao, Wei-Yu Liao, et al.Lung Cancer (Amsterdam, Netherlands)|March 17, 2015
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusionTzu-Hsiu Tsai, Shang-Gin Wu, Min-Shu Hsieh, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 8, 2016
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with OsimertinibChao-Chi Ho, Wei-Yu Liao, Chih-An Lin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2020
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 CasesJames Chih-Hsin Yang, Martin Schuler, Sanjay Popat, et al.Case Reports in Oncology|October 11, 2016
Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung CancerShao-Lun Lu, Feng-Ming Hsu, Kuan-Yu Chen, et al.International Journal of Molecular Sciences|December 6, 2016
Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80Kuan-Hung Lin, Shu-Ting Hong, Hsiang-Tsui Wang, et al.European Journal of Cancer (Oxford, England : 1990)|August 18, 2012
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancerYu-Yun Shao, Wen-Yi Shau, Zhong-Zhe Lin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2012
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinumWei-Yu Liao, Jin-Yuan Shih, Gee-Chen Chang, et al.Journal of Geriatric Oncology|September 24, 2014
Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosisChia-Lin Hsu, Jen-Hau Chen, Kuan-Yu Chen, et al.Pageof 26